## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours ner response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Grant Sean					2. Issuer Name <b>and</b> Ticker or Trading Symbol Vera Therapeutics, Inc. [ VERA ]									k all applica Director Officer (			s) to Issue 10% Owr Other (sp	ner
(Last) (First) (Middle) C/O VERA THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/15/2023						Λ	below)	) Chief Financial		below) Officer			
8000 MARINA BOULEVARD, SUITE 120					If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street) BRISBANE CA 94005				*-	4. II Amendment, Date of Original Filed (Molful/Day/feal)							Line)	ne)					
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				te	Execution Date,		Date,	Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				5. Amoun Securities Beneficial Owned Fo Reported	s F	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
							Code	v	Amount (A) or (D)		Prio	се	Transaction(s) (Instr. 3 and 4)				1150. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)			B. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	y Di or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		kpiration ate	Title	Amour or Number of Sha	er		(Instr. 4)	(5)		
Stock Option (right to buy)	\$7.87	02/15/2023		A		200,000		(1)	02	2/14/2033	Class A Common Stock	200,0	000	\$0.00	200,000	)	D	

## **Explanation of Responses:**

1. 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 15, 2023, subject to continuous service of the Reporting Person on each vesting date.

## Remarks:

/s/ Joseph R. Young, Attorneyin-Fact

02/17/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.